AUTHOR=Cooper Dylan J. , Zarabi Sharon , Farrand Brianna , Becker Amanda , Roslin Mitchell 

TITLE=Continuous glucose monitoring reveals similar glycemic variability in individuals with obesity despite increased HOMA-IR

JOURNAL=Frontiers in Nutrition

VOLUME=Volume 9 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1070187

DOI=10.3389/fnut.2022.1070187

ISSN=2296-861X

ABSTRACT=Abstract
Background/Aims: Continuous glucose monitoring is a well-tolerated and versatile tool for management of diabetes and metabolic disease. While its use appears to be feasible to monitor glycemic profiles in diabetics, there is a paucity of data in individuals with obesity and normal glucose tolerance. The aim of the study is to investigate glucose fluctuations and insulin resistance patterns in normoglycemic participants with obesity vs. without obesity and contextualize these results against leading models for obesity. 
Methods: We designed a prospective, observational pilot study of two cohorts including 14 normoglycemic participants with obesity and 14 normoglycemic participants without obesity. Participants were monitored with continuous glucose monitoring (CGM) for five consecutive days. Insulin resistance levels were measured and glucometric data were extracted from CGM for all participants. 
Results: Fasting serum insulin and HOMA-IR were significantly higher in the group with obesity (P < 0.05). While the group with obesity had a higher mean blood glucose (MBG), mean amplitude of glycemic excursions (MAGE), and continuous overall glycemic action-1hour (CONGA-1), these differences were not significant. On univariate linear regression, insulin resistance (HOMA-IR) was associated with BMI, WC, participants with obesity, participants consuming a high glycemic diet, HbA1c, and fasting insulin levels. WC and fasting insulin levels remained predictors of HOMA-IR in our multivariate model.
Conclusion: While there is much excitement surrounding the use of commercial CGM products in obesity management, our results suggest that fasting insulin and HOMA-IR values may be more clinically useful than CGM data alone.